Opinions Archives - Page 3 of 5 - Action Santé Mondiale

One of the major barriers that low- and middle-income countries report, is a lack of finance for climate and health investments.

Blog series

Funding and quality of aid, Research and Development

One of the major barriers that low- and middle-income countries report, is a lack of finance for climate and health investments.

By Marco Schäferhoff, PhD, Managing Director at Open Consultants.

actionsantemondiale14 November 2023

Health Day is an incredible opportunity to raise awareness of the links between health and climate change.

Blog series

Funding and quality of aid, Research and Development

Health Day is an incredible opportunity to raise awareness of the links between health and climate change.

By Jessica Beagley, Policy expert in health, environment and climate change at The Global Climate and Health Alliance.

actionsantemondiale14 November 2023

I believe it is a priority to promote the development of AI tools in Europe using European data sets.

Blog series

Research and Development

I believe it is a priority to promote the development of AI tools in Europe using European data sets.

By Jean-Emmanuel Bibault, Professor of Oncology and Radiotherapy and Researcher in artificial intelligence at the Georges Pompidou European Hospital.

actionsantemondiale8 November 2023

The GDPR does apply to AI in healthcare. However, data protection regulations do not resolve certain issues such as bias.

Blog series

Research and Development

The GDPR does apply to AI in healthcare. However, data protection regulations do not resolve certain issues such as bias.

By Cécile Crichton, PhD student at the Université Paris Cité and lecturer for the Master's Degree in Artificial Intelligence Law at the Institut Catholique de…

actionsantemondiale8 November 2023

The main limitation of the AI Act for healthcare is that it is a ‘horizontal’ act […]. This has consequences for the protection it offers to patients.

Blog series

Research and Development

The main limitation of the AI Act for healthcare is that it is a ‘horizontal’ act […]. This has consequences for the protection it offers to patients.

By Hannah van Kolfschooten, researcher and lecturer at the University of Amsterdam and consultant on patients' rights and european regulation of health AI for Health…

actionsantemondiale8 November 2023

If we have strong political will at the upcoming UNHLM on TB in September 2023, I genuinely believe we will be closer to our goal of ending TB by 2030.

Blog series

Promoting transparent and needs-driven EU R&D policies, Research and Development

If we have strong political will at the upcoming UNHLM on TB in September 2023, I genuinely believe we will be closer to our goal of ending TB by 2030.

By Rhea Lobo, an international award-winning filmmaker with a background in health journalism, a Tuberculosis (TB) survivor and a Board Member of the Stop TB…

actionsantemondiale13 June 2023

It’s a crucial moment for us in TB. We have so many opportunities in terms of R&D that shouldn’t be wasted.

Blog series

Promoting transparent and needs-driven EU R&D policies, Research and Development

It’s a crucial moment for us in TB. We have so many opportunities in terms of R&D that shouldn’t be wasted.

By Dr. Lucica Ditiu, a Romanian physician and Executive Director of the Stop TB Partnership.

actionsantemondiale13 June 2023

There really are grounds for optimism, but investment is still too low.

Blog series

Promoting transparent and needs-driven EU R&D policies, Research and Development

There really are grounds for optimism, but investment is still too low.

By Olivier Neyrolles, a researcher at CNRS and the director of IPBS-Toulouse.

actionsantemondiale13 June 2023

We believe in alternative funding and pricing models that can encourage pharmaceutical companies to innovate and to charge reasonable prices

Blog series

Promoting transparent and needs-driven EU R&D policies

We believe in alternative funding and pricing models that can encourage pharmaceutical companies to innovate and to charge reasonable prices

By Ella Weggen, Global health advocate at Wemos

actionsantemondiale28 September 2022

It is clear that transparency creates trust, and that the Political institutions should be irreproachable in that regard

Blog series

Promoting transparent and needs-driven EU R&D policies

It is clear that transparency creates trust, and that the Political institutions should be irreproachable in that regard

By Tilly Metz, Member of the EU Parliament

actionsantemondiale28 September 2022

Previous 1 2 3 4 5 Next

One of the major barriers that low- and middle-income countries report, is a lack of finance for climate and health investments.

Health Day is an incredible opportunity to raise awareness of the links between health and climate change.

I believe it is a priority to promote the development of AI tools in Europe using European data sets.

The GDPR does apply to AI in healthcare. However, data protection regulations do not resolve certain issues such as bias.

The main limitation of the AI Act for healthcare is that it is a ‘horizontal’ act […]. This has consequences for the protection it offers to patients.

If we have strong political will at the upcoming UNHLM on TB in September 2023, I genuinely believe we will be closer to our goal of ending TB by 2030.

It’s a crucial moment for us in TB. We have so many opportunities in terms of R&D that shouldn’t be wasted.

There really are grounds for optimism, but investment is still too low.

We believe in alternative funding and pricing models that can encourage pharmaceutical companies to innovate and to charge reasonable prices

It is clear that transparency creates trust, and that the Political institutions should be irreproachable in that regard

Addresses

Social Networks

Contact us